Semaglutide mastery course
Unit 7 of 12
Kidney and liver
Two of the newest indications take semaglutide into the kidney and the liver. The FLOW trial showed reduced kidney even…
Protecting the kidneys and treating fatty liver
Two of the newest indications take semaglutide into the kidney and the liver. The FLOW trial showed reduced kidney events in type 2 diabetes with chronic kidney disease, and liver-histology data behind an accelerated approval target MASH with fibrosis.
This unit reads the renal hazard ratio and the MASH histology endpoints, then weighs how solid each really is, since accelerated approval is meaningful but provisional.